Definium Therapeutics Shares Jump Following Positive Phase 3 Emerge Results
Definium Therapeutics reported positive topline outcomes from its Phase 3 Emerge study of DT120 Orally Disintegrating Tablet in major depressive disorder (MDD). The trial met its primary endpoint at Week 6 and all key secondary efficacy endpoints, producing significant placebo-adjusted improvements on the MADRS scale and prompting a sharp rise in t…